About
Building systemic intelligence for precision care
Cardiomnis AI Private Limited is a Chennai-based health technology company developing AI-enabled clinical intelligence and workflow solutions for chronic disease care.
Our initial focus is chronic kidney disease detection-to-prevention for people living with type 2 diabetes and hypertension. Our broader vision extends across interconnected cardio-renal-metabolic and pulmonary conditions.
Our mission
To help healthcare organisations identify preventable risk earlier and translate clinical information into coordinated, measurable action.
Our vision
A healthcare system in which chronic disease intelligence is proactive, connected and available at every important point in the care pathway.
Our name
Why Cardiomnis
The name Cardiomnis combines a cardio-led clinical foundation with an “omnis” or whole-system perspective.
It reflects our belief that chronic disease cannot be understood through a single organ, test or encounter. Cardiovascular, renal, metabolic and pulmonary risks are interconnected—and the intelligence supporting care should be equally connected.
Focus areas
What we are building
Our platform work spans the full detection-to-prevention pathway, and we aim to develop and validate it step by step with healthcare partners, subject to appropriate approvals and agreements.
- Disease-risk stratification
- Care-gap identification
- Clinical workflow intelligence
- Population-health management
- Referral and follow-up coordination
- Research and real-world evidence
- Preventive chronic disease programmes
Leadership
Founder
Ashwin Kumaar Murali Dharan
Founder, Cardiomnis AI
Ashwin leads the development of Cardiomnis AI’s company strategy, clinical problem selection, product direction, partnerships, regulatory planning and commercialisation.
His focus is building clinically relevant and commercially sustainable intelligence products for chronic disease detection, prevention and care coordination.
Based in Chennai, Tamil Nadu, India
Partner with Cardiomnis AI
We welcome conversations with healthcare organisations, researchers, incubators and investors.